Australia's Atomo Diagnostics jumps on new liver test license
20/01/2026 24:40
** Atomo Diagnostics AT1.AX jumps 11.4% to A$0.039; set for strongest trading session since December 9, 2025 ** Medical devices co signs exclusive global licensing agreement with Burnet Diagnostics Initiative for novel liver function test ** Says license for Burnet's liver function test supports commercialisation of rapid test for immediate detection of liver injury ** Test can be administered via co's self-testing device Pascal cassette ** YTD, AT1 up 5.6%; had risen 89.5% in 2025 (Reporting by Shruti Agarwal in Bengaluru) ((Shruti.Agarwal@thomsonreuters.com))
Recent news on Atomo Diagnostics
See all newsBrief: Atomo Diagnostics Undertakes Capital Raising To Raise Up To A$4.0 Million
Australia's Atomo Diagnostics slumps on discounted capital raising
Brief: Atomo Diagnostics Seeks Trading Halt
Brief: Atomo Diagnostics Secures Exclusive Licence For Novel Liver Function Test On Pascal
Australia's Atomo Diagnostics jumps on new liver test license